Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have been assigned an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $65.17.
A number of research analysts recently issued reports on ASTH shares. TD Cowen initiated coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. KeyCorp started coverage on shares of Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. BTIG Research upped their price target on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Finally, Robert W. Baird raised their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th.
View Our Latest Stock Analysis on ASTH
Astrana Health Trading Down 2.2 %
Astrana Health (NASDAQ:ASTH – Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $478.71 million during the quarter, compared to the consensus estimate of $462.01 million. During the same quarter in the prior year, the firm posted $0.47 earnings per share. On average, equities analysts forecast that Astrana Health will post 1.16 EPS for the current fiscal year.
Hedge Funds Weigh In On Astrana Health
Several institutional investors have recently bought and sold shares of the company. State Street Corp acquired a new position in Astrana Health during the 3rd quarter worth approximately $91,966,000. Geode Capital Management LLC purchased a new stake in shares of Astrana Health in the third quarter valued at approximately $58,995,000. FMR LLC acquired a new position in Astrana Health during the third quarter worth $48,413,000. SteelPeak Wealth LLC purchased a new position in Astrana Health in the third quarter worth $39,398,000. Finally, Loomis Sayles & Co. L P acquired a new stake in Astrana Health in the third quarter valued at $30,251,000. 52.77% of the stock is owned by institutional investors and hedge funds.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Stories
- Five stocks we like better than Astrana Health
- Short Selling: How to Short a Stock
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- 3 Tickers Leading a Meme Stock Revival
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What is Short Interest? How to Use It
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.